COVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States.
Sci Data
; 9(1): 727, 2022 11 26.
Article
in English
| MEDLINE | ID: covidwho-2133502
ABSTRACT
Seroprevalence studies provide useful information about the proportion of the population either vaccinated against SARS-CoV-2, previously infected with the virus, or both. Numerous studies have been conducted in the United States, but differ substantially by dates of enrollment, target population, geographic location, age distribution, and assays used. This can make it challenging to identify and synthesize available seroprevalence data by geographic region or to compare infection-induced versus combined infection- and vaccination-induced seroprevalence. To facilitate public access and understanding, the National Institutes of Health and the Centers for Disease Control and Prevention developed the COVID-19 Seroprevalence Studies Hub (COVID-19 SeroHub, https//covid19serohub.nih.gov/ ), a data repository in which seroprevalence studies are systematically identified, extracted using a standard format, and summarized through an interactive interface. Within COVID-19 SeroHub, users can explore and download data from 178 studies as of September 1, 2022. Tools allow users to filter results and visualize trends over time, geography, population, age, and antigen target. Because COVID-19 remains an ongoing pandemic, we will continue to identify and include future studies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Seroepidemiologic Studies
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Sci Data
Year:
2022
Document Type:
Article
Affiliation country:
S41597-022-01830-4
Similar
MEDLINE
...
LILACS
LIS